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Abstract:  In  the  present  study,  we  investigated  the  antileishmanial  activity  of 
sesquiterpene  elatol,  the  major  constituent  of  the  Brazilian  red  seaweed 
Laurencia dendroidea (Hudson) J.V. Lamouroux, against L. amazonensis. Elatol after 72 h 
of treatment, showed an IC50 of 4.0 µM and 0.45 µM for promastigote and intracellular 
amastigote forms of L. amazonensis, respectively. By scanning and transmission electron 
microscopy, parasites treated with elatol revealed notable changes compared with control 
cells,  including:  pronounced  swelling  of  the  mitochondrion;  appearance  of  concentric 
membrane structures inside the organelle; destabilization of the plasma membrane; and 
formation of membrane structures, apparently an extension of the endoplasmic reticulum, 
which is suggestive of an autophagic process. A cytotoxicity assay showed that the action 
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of the isolated compound is more specific for protozoa, and it is not toxic to macrophages. 
Our studies indicated that elatol is a potent antiproliferative agent against promastigote and 
intracellular amastigote forms, and may have important advantages for the development of 
new anti-leishamanial chemotherapies. 
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1. Introduction 
Leishmania  amazonensis,  a  flagellated  protozoan  parasite,  is  the  causative  agent  of  human 
cutaneous leishmaniasis. In this infectious disease, a high proportion of cases evolve to severe anergic 
diffuse cutaneous leishmaniasis, which is severely debilitating and disfiguring [1,2]. Because of the 
devastating  consequences  to  the  patient,  it  is  recognized  as  a  special  public  health  problem  [3]. 
Cutaneous  leishmaniasis  is  endemic  in  88  countries  on  five  continents,  with  1–1.5  million  cases 
reported yearly worldwide [4,5]. Poor nutrition, infection, and other stresses predispose patients to 
increased morbidity and mortality. Moreover, cases of Leishmania and human immunodeficiency virus 
coinfection  have  recently  increased  [6,7].  No  vaccines  for  preventing  infection  are  currently 
available [8,9]. 
Pentavalent  antimonial  compounds,  sodium  stiboglucanate  (Pentostam),  and  meglumine 
antimoniate  (Glucantime),  have  been  recommended  as  the  first  line  of  drugs  in  the  treatment  of 
cutaneous leishmaniasis for 50 years. However, these substances cause toxic effects, including nausea, 
vomiting, diarrhea, skin eruptions, headache, dizziness, cardiac arrhythmia, and hypotension [10–12]. 
In  cases  of  resistance,  amphotericin  B  and  Pentamidine  are  the  main  alternative  drugs,  but  their 
frequent and severe side effects limit their use. There is an urgent need for new and more efficient 
therapies for leishmaniasis. 
Elatol was isolated from Laurencia elata for the first time by Sims et al. [13]. Various species of 
Laurencia  (order  Ceramiales,  family  Rhodomeleceae)  also  produce  the  sesquiterpene  elatol  as  its 
major secondary metabolite [14–19]. Several studies have shown that elatol plays important roles in 
ecological  interactions,  such  as  antiherbivore  activity  and  potential  defense  against  infection  by 
microorganisms  [13–16].  Recent  studies  have  shown  that  elatol  can  be  synthesized  in  the 
laboratory [20,21]. Therefore, this study investigated the antileishmanial activity of elatol isolated from 
the Brazilian red seaweed Laurencia dendroidea against the promastigote and intracellular amastigote 
forms of L. amazonensis. Additionally, we used electron microscopy techniques to evaluate the effect 
of elatol on the morphology and ultrastructure of the parasite. 
2. Results and Discussion  
Marine algae have been used in traditional remedies in Asian countries including China, Japan, and 
Korea [22]. Species of Laurencia (order Ceremiales, family Rhodomeleceae) have proved to be a rich 
source of halogenated secondary metabolites, predominantly sesquiterpenes, diterpenes, and C15 non 
terpenoids [23–25]. Probably, these halogenated metabolites defend against marine herbivores  and Mar. Drugs 2010, 8  
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infection by microorganisms [23,26–28]. Various studies have reported that seaweeds have shown 
important  biological  activities,  including  antibacterial,  antifungal,  antileishmanial,  antitrichomonal, 
antihelmintic,  antiviral,  antipyretic,  analgesic,  anti-inflammatory,  antioxidative,  and  anticoagulant 
[15,20,22,25,28–36]. In the present study, we assessed the antileishmanial activity of sesquiterpene 
elatol, the major constituent of the Brazilian red seaweed L. dendroidea (Hudson) J.V. Lamouroux, 
against  L.  amazonensis.  The  physical  and  spectroscopic  properties  of  the  sesquiterpene  elatol 
(Figure 1) were identical with data previously reported by Kö nig and Wright [14]. 
Figure 1. The chemical structure of elatol. 
 
Elatol  showed  a  dose-dependent  antileishmanial  activity  against  the  promastigote  forms. 
Concentrations of 4.0 ±  0.3 µM and 7.5 ±  0.5 µM of elatol induced 50% and 90% growth inhibition on 
L. amazonensis, respectively, after 72 h of treatment (Figure 2).  
Figure 2. Effect of elatol against promastigote forms of L. amazonensis. 
 
Figure 3 shows the effects of the elatol on the L. amazonensis-macrophage interaction. When the 
parasites  were  treated  with  elatol,  a  dose-dependent  decrease  of  intracellular  amastigotes  was 
observed. The survival index was calculated as 392.0 for 0.15 µM; 325.0 for 0.30 µM; and 230.0 for 
1.5  µM.  These  results  correspond  to  rates  of  inhibition  of  survival  as  high  as  57,  65,  and  75%, 
respectively. The IC50 for the intracellular amastigote form was 0.45 µM. The intracellular forms are a 
great challenge in the treatment of leishmaniasis. All the results were significant at p ≤ 0.05 compared 
to the control group, by Student’s t-test. Amphotericin B showed IC50 of 0.06 µM and 0.31 µM against 
the promastigote and intracellular amastigote forms, respectively. Elatol was also evaluated for its 
potential toxic effects on macrophage strain J774G8. When macrophages were treated with elatol, the 
50% cytotoxic concentration (CC50) was 1.4 µM. The toxicity to the macrophage and the activity 
against protozoa were compared by using the selectivity index (SI) (ratio: CC50 macrophage J774G8 
cells/IC50 protozoa). The observed SI for the intracellular amastigote forms was 3.0 times less toxic to 
the macrophage than to the protozoa. Mar. Drugs 2010, 8  
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Figure 3.  Survival index of L. amazonensis within peritoneal macrophage cells treated 
with elatol. * Significant difference of each group from the control (p < 0.05). 
 
By  scanning  electron  microscopy,  promastigote  forms  treated  with  elatol  revealed  notable 
morphological changes compared with the control cells (Figure 4A). There were changes in size and 
shape (Figure 4B, C, D, and F). In addition, cells showed rupture of the plasma membrane with loss of 
their contents (Figure 4C–F) and cell shrinkage (Figure 4F).  
Figure 4. Scanning electron microscopy of promastigote forms of L. amazonensis treated 
with elatol after incubation for 48 h at 25 ° C. (A) Control; (B–F) Parasites after treatment 
with IC50 of elatol. Bars = 1 µm. 
 
Photomicrographs from transmission electron microscopy are shown in Figure 5. Control parasites 
showed no changes in the plasma membrane, and an apparently normal ultrastructure (Figure 5A). In 
promastigote forms, the treatment with elatol led to a pronounced swelling of the mitochondrion and 
the appearance of concentric membrane structures inside the organelle (Figure 5C), destabilization of Mar. Drugs 2010, 8  
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the plasma membrane (Figure 5D), and autophagic vacuoles (Figure 5B). The treated cells also formed 
membrane structures, apparently an extension of the endoplasmic reticulum, which is suggestive of an 
autophagic process (Figure 5C). A similar structure was not seen in untreated cells. We also observed 
the  effects  of  elatol  on  intracellular  amastigote  forms.  Peritoneal  macrophages  were  infected  in 
multiples of 10 promastigotes per host cell, and were incubated at 37 ° C in 5% CO2 atmosphere. After 
24  h,  the  infected  macrophages  were  treated  with  elatol.  Figure  5E  shows  several  intracellular 
amastigotes in peritoneal macrophages. In the ultrastructural evaluation of treated amastigotes, the 
most prominent effect was swollen mitochondria (Figure 5E, F and G). 
Figure 5. Ultrastructural effect of elatol after incubation for 48 h at 25 ° C on promastigote 
and intracellular amastigote forms of L. amazonensis, observed by transmission electron 
microscopy.  (A)  Promastigote  control;  (B–D)  Promastigote  treated  with  IC50  of  elatol;  
(E–H) Intracellular amastigote forms treated with IC50 of elatol. Elatol treatment led to 
swelling of the mitochondria (white arrow), autophagic vacuoles (black stars), appearance 
of concentric membrane structures inside the organelle (asterisk), destabilization of the 
plasma membrane (arrowhead), extension of the endoplasmic reticulum (two arrows), and 
intracellular amastigotes in peritoneal macrophages (white star). n: nucleus; f: flagellum; 
fp: flagellar pocket; k: kinetoplast; m: mitochondrion; Bars = 1 µm.  
 Mar. Drugs 2010, 8  
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Interestingly, a similar mechanism is seen during treatment with ergosterol biosynthesis inhibitors. 
Lazardi et al. [37] showed that epimastigote and amastigote forms of Trypanosoma cruzi treated with 
the minimum growth-inhibitory concentration of ICI 195,739 (0.1 µM) displayed almost immediate 
ultrastructural alterations, consisting of membrane lesion, intense swelling of the mitochondrion with 
loss of the inner membrane, and changes in the matrix electron density, as well as the appearance of 
autophagic vacuoles. Similar results have been reported by Rodrigues et al. [38] in L. amazonensis 
promastigotes treated with azasterols, known inhibitors of the Δ
24(25)-sterol methyltransferase, showing 
several alterations in the mitochondrion structure such as disorganization of the internal membranes 
and an intense and evident mitochondrial swelling with loss of the matrix content. This is in agreement 
with Lorente et al. [39], who found similar alterations when parasites were treated with azasterols. 
These  compounds  were  shown  to  have  ultrastructural  effects  on  L.  amazonensis  promastigote 
membranes, including the plasma and mitochondrial membranes, and the endoplasmic reticulum. In 
addition, Rodrigues et al. [40] described the effects of sterol methenyl transferase inhibitors (SMTI), 
essential  enzymes  for  sterol  biosynthesis,  on  promastigote  and  axenic  amastigote  forms  of 
L. amazonensis. Ultrastructural alterations in treated cells were observed mainly in the mitochondrion, 
which displayed intense swelling and reduced electron density of the matrix, with marked changes in 
the inner mitochondrial membranes. 
3. Experimental Section  
3.1. Plant material and extraction procedures 
Specimens of L. dendroidea were collected by hand during low tide, in the midlittoral zone on the 
rocky coast of Cabo Frio Island (22°59’ S, 42°59’ W), Rio de Janeiro State, Brazil. This seaweed was 
previously described  as  L. obtusa,  but through molecular techniques, it was  recently identified as 
L. dendroidea [41]. The seaweed was stored in plastic bags and chilled on ice during transport to the 
laboratory. The specimens of L. dendroidea used in this study were identified by Dr. Mutue Toyota 
Fujii, and voucher specimens were deposited in the herbaria SP, Instituto de Botâ nica, Sã o Paulo State, 
Brazil (SP number: 399789). L. dendroidea was dried in the dark at room temperature. 
3.2. Extraction procedures and elatol isolation 
The air-dried algal  material (300.0  g)  giving 50 mg  of  elatol was  successive  and  exhaustively 
extracted  in  n-hexane  at  room  temperature  for  15  days.  The  n-hexane  crude  extract  (HE)  was 
evaporated to dryness on a rotary evaporator at low temperature (<50 ° C), yielding 3.64 g of a dark 
green extract containing the sesquiterpene elatol, which was detected as brown spot on TLC plates 
after spraying with a solution of ceric sulphate and sulfuric acid (2.1 g of Ce2(SO4)3· 4H2O; 21 mL of 
H2SO4 and 300 mL of H2O), followed by heating at 100 ° C for 3 min. An aliquot of HE (0.35 g) was 
submitted to preparative thin layer chromatography (PTLC) (Merck, silica gel 60 F254, 20 ×  20 cm, 
mobile phase: n-hexane/ethyl acetate 8:2), to afford a yellowish oil (50 mg) which was identified as the 
sesquitepene elatol. The purity was confirmed by TLC (Rf = 0.45), using  n-hexane/AcOEt 8:2 as 
mobile phase, and by 
1H-NMR spectroscopy (300 MHz). Mar. Drugs 2010, 8  
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3.3. Spectroscopic data 
The physical and spectroscopic properties of the isolated elatol were identical to those previously 
reported by Kö nig and Wright [42]. 
3.4. Parasite and cell culture 
Promastigote forms of L. amazonensis (MHOM/BR/75/Josefa strain) were maintained by weekly 
transfers in Warren’s medium [43] supplemented with 10% heat-inactivated fetal bovine serum (FBS) 
at 25 ° C in a tissue flask. The macrophage lineage (J774G8) was maintained in tissue flasks in RPMI 
1640  medium  (Gibco  Invitrogen  Co.,  Grand  Island,  New  York,  U.S.)  with  L-glutamine  and 
supplemented with 10% inactivated fetal bovine serum at 37 ° C in a 5% CO2–air mixture. 
3.5. Antileishmanial activity 
L. amazonensis promastigotes (1 ×  10
6 parasites/mL) were inoculated in a 24-well plate containing 
Warren’s medium supplemented with 10% inactivated fetal bovine serum with different concentrations 
of elatol (0.1 to 100 µM), and incubated at 25 ° C for 72 h. The cell density for each concentration was 
determined by counting in a hemocytometer (Improved Double Neubauer). Amphotericin B was used 
as a positive control. Controls containing 1.0% dimethyl sulfoxide (DMSO; Sigma Chemical Co., 
St. Louis, Missouri, U.S.) and medium alone were also included. The results were expressed by IC50 
(concentration that inhibited 50% parasite growth). 
3.6. Activity against intracellular amastigotes 
After 72 h of inoculation of 5% thioglycolate medium, resident peritoneal cells from the BALB/c 
mice were harvested in RPMI 1640 medium (Gibco Invitrogen Corporation, New York, U.S.) pH 7.6. 
Cells were plated on coverslips (diameter 13 mm) in 24-well plates and allowed to adhere for 24 h at 
37 ° C in 5% CO2 atmosphere. Macrophages were infected in multiples of 10 promastigotes per host 
cell and were incubated at 37 ° C in 5% CO2 atmosphere. After 24 h, infected macrophages were 
treated with different concentrations of elatol (0.15 to 1.50 µM). Next, the monolayers were washed 
with PBS at 37 ° C, fixed in methanol, and stained with Giemsa. The number of amastigotes was 
determined by counting at least 200 macrophages in duplicate cultures, and the results were expressed 
as  the survival  index. The survival  index was  obtained by multiplying the percentage of infected 
macrophages by the number of amastigotes per infected macrophage. 
3.7. Cytotoxicity assay 
Adherent  J774G8  macrophage  cells  in  the  logarithmic  growth  phase  were  suspended  to  yield 
10
5 cells/mL in RPMI 1640 medium supplemented with 10% FBS, and added to each well in 96-well 
microtiter plates. The plates were incubated in a 5% CO2–air mixture at 37 ° C to obtain confluent cell 
growth. After 24 h, the medium was removed and the cells were treated with elatol (0.1 to 100 µM). 
Control wells without elatol were included. The plates were incubated in a 5% CO2–air mixture at 
37 ° C for 48 h. The cultures were then fixed with 10% trichloroacetic acid for 1 h at 4 ° C, stained for Mar. Drugs 2010, 8  
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30 min with 0.4% sulforhodamine B (SRB) in 1% acetic acid and subsequently washed five times with 
deionized water. Bound SRB was solubilized with 200 µL 10 mM unbuffered Tris-base solution. 
Absorbance was read in a 96-well plate reader (BIO-TEK Power Wave XS) at 530 nm. Dose-response 
curves  were  plotted  (values  expressed  as  percentage  of  control  optical  density)  and  CC50  values 
(50% cytotoxicity concentration) were estimated by regression analysis. 
3.8. Electron microscopy 
Promastigote and intracellular amastigote forms were treated with IC50 of elatol at 25 ° C for 24 and 
48 h, respectively. The parasites were fixed in 2.5% glutaraldehyde in 0.1 M cacodylate buffer, pH 7.2. 
For  transmission  electron  microscopy,  cells  were  postfixed  for  40  min  in  a  solution  containing 
1% OsO4 and 0.8% potassium ferrocyanide in 0.1 M cacodylate buffer, washed in the same buffer, 
dehydrated in acetone, and embedded in Epon. Ultrathin sections were stained with uranyl acetate and 
lead  citrate,  and  were  observed  in  a  Zeiss  900  electron  microscope.  For  observation  by  scanning 
electron microscope, promastigotes were placed on a specimen support with poly-L-lysine, dehydrated 
in  graded  ethanol,  critical-point  dried  in  CO2,  coated  with  gold,  and  observed  in  a  Shimadzu  SS 
550 SEM. 
3.9. Statistical analysis 
The means and standard deviations were determined from at least three experiments. All tests were 
done in duplicate. Statistical analysis was performed with the program GraphPad Prism 4 (GraphPad 
Software, San Diego, California, U.S.). Student’s t test was applied, and a p value less than 0.05 was 
regarded as significant. 
4. Conclusions 
Our  studies  indicated  that  elatol  is  a  potent  antiproliferative  agent  against  promastigote  and 
intracellular amastigote forms of L. amazonensis, and induced notable changes in the ultrastructure of 
the mitochondrion of the parasite. Laboratory synthesis and the possibility of modifying the chemical 
structure  of  elatol  may  lead  to  important  advances  in  the  development  of  new  anti-leishmanial 
chemotherapies. More in vitro and in vivo studies will be carried out to increase understanding of the 
mode of action of this drug and its future utilization in the treatment of leishmaniasis. 
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